NEW ORLEANS– At the American Associate Association for Cancer Research 2016 Annual Meeting (Booth #438), The Jackson Laboratory, a global leader in mammalian cancer genetics modeling and education and human genomics, will launch a full suite of solutions designed to accelerate cancer research.
Humanized NSG™-SGM3: Humanized NSG and NSG-SGM3 mice represent innovative and cost-effective immuno-oncology platforms to simulate trials, evaluate multiple drugs alone or in combination, and produce predictive data. The Jackson Laboratory’s NSG-SGM3 strain allows for the superior development of myeloid and CD4+ T cell populations after human hematopoietic stem cell transplantation, thereby enabling a more accurate representation of the human immune system. This model is expected to accelerate research in immuno-oncology, immunology, and infectious disease. The triple transgenic NSG-SGM3 strain shares the same genetic background as the popular NSG, while expressing human IL3, GM-CSF, and SCF. This strain allows the stable engraftment and differentiation of myeloid lineages and regulatory T cell (Treg) populations, making it especially suitable for immuno-oncology studies. Study ready hu-NSG and hu-NSG-SGM3 cohorts are available immediately for shipments worldwide. For more information, visit jax.org/humanized-mice.
PDX Live™: JAX now offers optimized Patient Derived Xenograft (PDX) efficacy studies utilizing its PDX Live library. These select tumors are kept at low passage in live donor mice, enabling fast-tracked efficacy testing studies for pre-clinical cancer drug development, potentially saving months of pre-study time. For more information, visit jax.org/pdx-live.
Onco-hu™: Onco-Hu models are a robust immuno-oncology platform for efficacy testing of novel immunotherapies targeting T cells and myeloid cells to help destroy cancers in vivo. The Onco-Hu platform is based on NSG and NSG-SGM3 mice, dually engrafted with human CD34+ hematopoietic stem cells and clinically relevant PDX low passage tumors. Onco-Hu models better recapitulate human tumor and immune cell interactions in vivo compared to existing models, allowing improved physiological modeling of pathways important in therapeutic intervention.
“This is a very exciting development,” states Dr. Walter Ausserer, Business Director for Clinical & In Vivo Services at The Jackson Laboratory. “Our new humanized mice enable researchers studying immuno-oncology to obtain results from mouse studies that may be more predictive of therapeutic response in humans.”
“These models represent an important step toward modulating the immune system to recognize and attack tumors,” Dr. Ausserer says. “Most importantly,” he adds, “data show that immuno-modulatory drugs can be effective in these models, including checkpoint inhibitors like anti-PD-1 antibodies.” For more information, visit jax.org/onco-hu.
The Jackson Laboratory will host a series of in-booth presentations on topics including humanized NSG-SGM3, PDX Live, and Onco-Hu mouse models. Talks will run for approximately 20 minutes; speakers will be available for Q&A following each presentation. For more information, visit booth #438 or jax.org/aacr-2016.
The Jackson Laboratory will also feature several poster presentations at AACR 2016:
JAX representatives will be at the AACR career fair on Saturday, April 16 at booth #CF100 and in the main exhibitor hall at booth #438 to speak with interested faculty and postdoctoral candidates.
The Jackson Laboratory is a global leader in mammalian cancer genetics modeling and education, and has been a driving force supporting oncology research and discovery for over 85 years. The Laboratory is using the latest research methods and tools to investigate a variety of cancers, including breast, lung, brain, gastric and blood. Its recently created Jackson Laboratory for Genomic Medicine in Farmington, Connecticut will deepen its cancer research programs, accelerating the discovery of precise genomic medical solutions for disease. Additional information is available on jax.org.